HYDERABAD (Reuters) - Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

Medtronic (MDT) is reportedly looking at adjusting its global manufacturing footprint amid heightened concerns that the U.S.

Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

ViCentra announced today that it appointed Tom Arnold as its new CEO to accelerate growth with the Kaleido automated insulin ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...

The BrainSense Adaptive technology is an enhancement to Medtronic’s Percept DBS neurostimulators. The advancement ...